查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1880627

大環內酯類抗生素市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Macrolide Antibiotics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

大環內酯類抗生素市場成長驅動因子

受細菌感染日益普遍以及對先進抗菌療法需求不斷增長的推動，全球大環內酯類抗生素市場持續穩步增長。根據最新的產業評估，預計到 2024 年，該市場規模將達到 59.6 億美元，這主要得益於大環內酯類抗生素在呼吸道感染、皮膚感染和性傳染感染治療中的高處方量和廣泛應用。到 2025 年，預計該市場規模將擴大至 61.6 億美元，這主要得益於對生物利用度更高、抗藥性更低的抗生素的需求不斷增長。預計到2032年，大環內酯類抗生素市場規模將達到80.6億美元，2025年至2032年的複合年增長率（CAGR）為3.9%。北美將在2024年佔市場主導地位，市佔率將達到28.3億美元（47.48%）。這主要得益於北美強大的醫療基礎設施、較高的抗生素消費量以及持續的藥物研發活動。

大環內酯類抗生素透過與50S核醣體亞基可逆結合，抑制細菌蛋白質合成，進而發揮抗菌作用。新一代大環內酯類抗生素，如阿奇黴素和克拉黴素，具有廣譜抗菌、更優的藥物動力學特性和更高的安全性，其臨床應用日益廣泛。這些藥物發揮著至關重要的作用，尤其是在兒科護理中，因為在兒科護理中，不建議使用氟喹諾酮類等替代藥物。

市場推動因素

市場成長的主要推動因素是全球細菌感染（特別是呼吸道感染、性傳染感染和皮膚感染）的增加趨勢。根據世界衛生組織（2024年7月）的數據，15至49歲成年人中報告了8240萬例新的淋病病例，這顯著增加了對阿奇黴素和類似大環內酯類藥物的需求。處方量的增加也推動了市場的發展勢頭，2023年美國零售藥局每1,000人約配發105份大環內酯類藥物。

新型大環內酯類藥物的改良配方也是推動市場成長的因素。 2023年10月，美國FDA核准Fathom Pharmaceuticals公司的VOQUEZNA TRIPLE PAK和DUAL PAK用於治療幽門螺旋桿菌感染，將推動含克拉黴素治療方案的廣泛應用。

市場限制因子

主要阻礙因素之一是與生產缺陷、無菌問題和標籤問題相關的召回事件日益增多。這些召回事件損害了品牌形象，削弱了消費者信心。例如，2025年2月，新加坡衛生科學局因無菌問題召回了克拉黴素Evert 500mg。同樣，英國藥品和保健產品監管局（MHRA）於2023年12月宣布召回多種克拉黴素片劑。這些反覆發生的事件給監管和市場推廣帶來了挑戰。

市場機會

在細菌感染率較高的亞洲、非洲和拉丁美洲，隨著各國政府加強對本土藥物研發的支持力度，巨大的市場機會正在湧現。一個顯著的例子是印度在生物製品資訊研究援助委員會 (BIRAC) 的支持下於 2024 年 11 月推出的萘菲黴素 (nafithromycin)。該藥物用於治療社區型細菌性肺炎 (CABP)。國產新藥的上市將提高藥物的可近性和可負擔性，從而擴大發展中地區的市場潛力。

區域展望

北美

預計到 2024 年，北美市場規模將達到 28.3 億美元，由於其高發病率、強大的研發投入以及在對抗抗生素抗藥性方面的大量投資，北美仍然是全球領先市場。美國繼續主導該地區的需求，這得益於聯邦政府的撥款，例如美國國家過敏症和傳染病研究所 (NIAID) 於 2024 年 5 月撥款 270 萬美元用於大環內酯類抗藥性研究。

歐洲

歐洲佔第二大市場佔有率，主要得益於廣譜抗生素消費量的成長。區域研究表明，2019年至2021年間，抗生素使用量激增，推動了用於治療呼吸道和胃腸道感染的大環內酯類抗生素的需求。

亞太地區

預計到2032年，亞太地區將維持最高的複合年增長率，這主要得益於醫療保健服務的改善、疾病負擔沉重以及人口的快速增長。例如，世界衛生組織於2024年預先批准孟加拉國的Rockville阿奇黴素500毫克，這將進一步鞏固區域市場的成長。

拉丁美洲、中東/非洲

由於細菌感染病例的增加和國際合作的加強，這些地區的需求正在溫和增長。例如，輝瑞公司於 2022 年 6 月向世界衛生組織捐贈了阿奇黴素，加強了沙眼流行國家獲得這種抗生素的機會。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 2024年主要國家和地區主要疾病盛行率
  • 主要公司產品線分析
  • 主要產業趨勢（併購、合作等）
  • 主要國家和地區的監管和報銷情況

第五章：全球大環內酯類抗生素市場分析洞察與預測 (2019-2032)

  • 市場分析、洞察與預測 - 依產品劃分
    • 阿奇黴素
    • 克拉黴素
    • 奧利黴素
    • 紅黴素
    • 其他
  • 市場分析、洞察與預測 - 依疾病劃分
    • 呼吸道感染
    • 皮膚感染
    • 性傳染感染 (STI)
    • 其他
  • 市場分析、洞察與預測 - 依給藥途徑劃分
    • 口服
    • 注射
    • 其他
  • 市場分析、洞察與預測 - 依年齡劃分組別
    • 成人
    • 兒科
  • 市場分析、洞察與預測 - 依分銷管道劃分
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美大環內酯類抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲大環內酯類抗生素市場分析、洞察與預測2019-2032

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區大環內酯類抗生素市場分析、洞察與預測，2019-2032

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲大環內酯類抗生素市場分析、洞察與預測，2019-2032

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東和非洲大環內酯類抗生素市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Crescent Pharma Ltd.
    • Wellona Pharma
    • Zydus Group
    • Merck &Co., Inc.
    • Alkem
    • Azurity Pharmaceuticals, Inc.
    • Lupin
    • Sun Pharmaceutical Industries Ltd.
Product Code: FBI113847

Growth Factors of macrolide antibiotics Market

The global macrolide antibiotics market continues to grow steadily as the burden of bacterial infections rises worldwide and the need for advanced antimicrobial therapies accelerates. According to the latest industry assessment, the market size reached USD 5.96 billion in 2024, driven by high prescription volumes and widespread utilization of macrolides for respiratory, skin, and sexually transmitted infections. In 2025, the market is expected to rise to USD 6.16 billion, supported by increasing demand for antibiotics with improved bioavailability and reduced microbial resistance. By 2032, the macrolide antibiotics market is projected to reach USD 8.06 billion, expanding at a CAGR of 3.9% from 2025-2032. In 2024, North America dominated the market with a 47.48% share, valued at USD 2.83 billion, attributed to strong healthcare infrastructure, high antibiotic consumption, and ongoing drug development activities.

Macrolide antibiotics function by inhibiting bacterial protein synthesis through reversible binding to the 50S ribosomal subunit. With their broad-spectrum antimicrobial capabilities, enhanced pharmacokinetics, and improved safety profile, next-generation macrolides such as azithromycin and clarithromycin continue to gain strong clinical adoption. They are especially vital in pediatric care, where alternatives such as fluoroquinolones are not recommended.

Market Drivers

A key driver of market growth is the increasing global prevalence of bacterial infections, particularly respiratory infections, sexually transmitted diseases (STIs), and skin infections. According to WHO (July 2024), 82.4 million new gonorrhea cases were reported among adults aged 15-49 years, significantly increasing demand for azithromycin and similar macrolides. Rising prescription volumes further strengthen market momentum, with U.S. retail pharmacies dispensing around 105 macrolide prescriptions per 1,000 population in 2023.

New macrolide drug reformulations are also fueling growth. The U.S. FDA approval in October 2023 for Phathom Pharmaceuticals' VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection has enhanced adoption of clarithromycin-inclusive treatment regimens.

Market Restraints

One of the major restraints is the growing number of product recalls linked to manufacturing defects, sterility issues, and labeling problems. Such recalls damage brand reputation and hinder consumer trust. For example, in February 2025, Singapore's Health Sciences Authority recalled Clarithromycin Eberth 500 mg due to failed sterility tests. Similarly, the U.K.'s MHRA issued multiple recalls for clarithromycin tablets in December 2023. These recurring incidents create regulatory and market-adoption challenges.

Market Opportunities

Significant opportunities are emerging across Asia, Africa, and Latin America, where bacterial infection rates remain high, and governments increasingly support indigenous drug development. A notable example includes India's launch of Nafithromycin in November 2024, developed with BIRAC support to target community-acquired bacterial pneumonia (CABP). New domestic drug launches enhance accessibility and affordability, expanding market potential in developing regions.

Regional Outlook

North America

With a market value of USD 2.83 billion in 2024, North America remains the global leader due to high disease prevalence, strong R&D initiatives, and significant investment in combating antibiotic resistance. The U.S. continues to dominate regional demand, supported by federal grants such as the USD 2.7 million NIAID funding in May 2024 for macrolide-resistance research.

Europe

Europe holds the second-largest share, driven by increased consumption of broad-spectrum antibiotics. Regional studies show a surge in antibiotic use between 2019-2021, boosting demand for macrolides used in respiratory and gastrointestinal infections.

Asia Pacific

Asia Pacific is anticipated to record the highest CAGR through 2032, supported by improving healthcare access, high disease burden, and rapid population growth. Advancements such as WHO prequalification of Bangladesh-based Rockville's azithromycin 500 mg in 2024 further strengthen regional market progress.

Latin America & Middle East/Africa

These regions show moderate but expanding demand, driven by rising bacterial infections and international collaborations. For instance, Pfizer's donation of Zithromax to WHO in June 2022 strengthens antibiotic access in trachoma-endemic nations.

Competitive Landscape

The market is semi-consolidated with leading companies such as Pfizer, Teva Pharmaceutical Industries, Merck & Co., Aurobindo Pharma, Lupin, Zydus Group, and Sun Pharma. Key strategies include generic launches, investments in R&D, and partnerships with regulatory agencies. Ongoing developments-such as Aurobindo's U.S. FDA approval for azithromycin and Alembic's clarithromycin ANDA approval-continue to shape the competitive environment.

Conclusion

Supported by rising infection rates, expanded drug development, and strong adoption across pediatric and adult populations, the macrolide antibiotics market is expected to grow from USD 5.96 billion in 2024 to USD 8.06 billion by 2032. Continuous research, international collaborations, and improved drug formulations will remain key growth accelerators throughout the forecast period.

Segmentation By Product

  • Azithromycin
  • Clarithromycin
  • Oleandomycin
  • Erythromycin
  • Others

By Disease Indication

  • Respiratory Infections
  • Skin Infections
  • Sexually Transmitted Diseases (STIs)
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Age Group

  • Adults
  • Pediatrics

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases- by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.4. Regulatory & Reimbursement Scenarios, By Key Countries/ Regions

5. Global Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Azithromycin
    • 5.1.2. Clarithromycin
    • 5.1.3. Oleandomycin
    • 5.1.4. Erythromycin
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Respiratory Infections
    • 5.2.2. Skin Infections
    • 5.2.3. Sexually Transmitted Diseases (STIs)
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Adults
    • 5.4.2. Pediatrics
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Azithromycin
    • 6.1.2. Clarithromycin
    • 6.1.3. Oleandomycin
    • 6.1.4. Erythromycin
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Respiratory Infections
    • 6.2.2. Skin Infections
    • 6.2.3. Sexually Transmitted Diseases (STIs)
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Adults
    • 6.4.2. Pediatrics
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Azithromycin
    • 7.1.2. Clarithromycin
    • 7.1.3. Oleandomycin
    • 7.1.4. Erythromycin
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Respiratory Infections
    • 7.2.2. Skin Infections
    • 7.2.3. Sexually Transmitted Diseases (STIs)
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Adults
    • 7.4.2. Pediatrics
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Azithromycin
    • 8.1.2. Clarithromycin
    • 8.1.3. Oleandomycin
    • 8.1.4. Erythromycin
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Respiratory Infections
    • 8.2.2. Skin Infections
    • 8.2.3. Sexually Transmitted Diseases (STIs)
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Adults
    • 8.4.2. Pediatrics
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Azithromycin
    • 9.1.2. Clarithromycin
    • 9.1.3. Oleandomycin
    • 9.1.4. Erythromycin
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Respiratory Infections
    • 9.2.2. Skin Infections
    • 9.2.3. Sexually Transmitted Diseases (STIs)
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Adults
    • 9.4.2. Pediatrics
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Macrolide Antibiotics Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Azithromycin
    • 10.1.2. Clarithromycin
    • 10.1.3. Oleandomycin
    • 10.1.4. Erythromycin
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Respiratory Infections
    • 10.2.2. Skin Infections
    • 10.2.3. Sexually Transmitted Diseases (STIs)
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Adults
    • 10.4.2. Pediatrics
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Crescent Pharma Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Wellona Pharma
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Zydus Group
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Alkem
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Azurity Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Lupin
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Sun Pharmaceutical Industries Ltd.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 2: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 3: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 4: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 5: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 8: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 9: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table10: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 11: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 14: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 15: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 16: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 17: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 19: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 20: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 21: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 22: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 23: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 26: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 27: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 28: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 29: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 32: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2019-2033
  • Table 33: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2034
  • Table 34: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2019-2034
  • Table 35: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Macrolide Antibiotics Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Macrolide Antibiotics Market Value Share (%), by Product, 2024 & 2032
  • Figure 3: Global Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024 & 2032
  • Figure 4: Global Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 5: Global Macrolide Antibiotics Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 6: Global Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global Macrolide Antibiotics Market Value Share (%), by Region, 2024 & 2032
  • Figure 8: North America Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 9: North America Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 10: North America Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 11: North America Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 12: North America Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 13: North America Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 14: North America Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 15: North America Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 16: North America Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America Macrolide Antibiotics Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Macrolide Antibiotics Market Value Share (%), By Country, 2024
  • Figure 20: Europe Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 21: Europe Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 22: Europe Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 23: Europe Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 24: Europe Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 25: Europe Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 26: Europe Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 27: Europe Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 28: Europe Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 33: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 34: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 35: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 36: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 37: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 38: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 39: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 40: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 45: Latin America Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 46: Latin America Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 47: Latin America Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 48: Latin America Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 49: Latin America Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 50: Latin America Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 51: Latin America Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 52: Latin America Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Product, 2024 & 2032
  • Figure 57: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Product, 2024
  • Figure 58: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2024 & 2032
  • Figure 59: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2024
  • Figure 60: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 61: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2024

2024 & 2032

  • Figure 62: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 63: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Age Group, 2024
  • Figure 64: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Macrolide Antibiotics Market Share (%), By Company, 2024